FDA Approves Updated mRNA COVID-19 Vaccines with Age and Health Condition Restrictions

Strategic Insights -

The FDA has granted approval for updated mRNA COVID-19 vaccines from Pfizer and Moderna, but with significant restrictions on their use. Unlike previous endorsements, the new vaccines are only approved for people with underlying health conditions, excluding those without them, regardless of age. The vaccines target the LP.8.1 sublineage of the SARS-CoV-2 virus and are designed to ensure robust supply and rapid access across the country.

Key Takeaways:

  • The updated mRNA COVID-19 vaccines from Pfizer and Moderna have been approved by the FDA, but with restrictions on their use.
  • The vaccines are only approved for people with underlying health conditions, excluding those without them, regardless of age.
  • High-risk conditions for severe COVID include asthma, cancer, chronic kidney disease, diabetes, and many others, as per the Centers for Disease Control and Prevention (CDC).
  • The updated Comirnaty vaccine is approved for use in people ages 5-64 years with underlying conditions, and for all individuals 65 and older.
  • Moderna's Spikevax is approved for use in babies as young as six months, but with similar restrictions on underlying conditions.
  • Novavax's protein-based vaccine is approved for people 12 years and older, but with similar stipulations around underlying conditions.
  • The FDA has revoked prior Emergency Use Authorizations (EUAs) for COVID-19 vaccines, leaving Pfizer and BioNTech's vaccine only endorsed for children 5 years and older.
  • Pfizer and BioNTech are expected to run a study of their shot in adults ages 50-64 years without underlying conditions, with final results due in 2027.

Statistics:

  • 64% of Americans 64 and younger may be excluded from receiving the updated mRNA COVID-19 vaccines due to the underlying health condition requirement.
  • The price of Novavax's protein-based vaccine is not yet disclosed.
  • It is estimated that the updated vaccines will be available for distribution "immediately," according to Pfizer and BioNTech.
  • The FDA has conducted new trials for COVID-19 vaccine manufacturers, including a study on Pfizer and BioNTech's shot in adults ages 50-64 years without underlying conditions.
  • 2027 is the expected final result date for the study on Pfizer and BioNTech's shot in adults ages 50-64 years without underlying conditions.

Sources:

  • Pfizer and BioNTech's Comirnaty vaccine approval
  • Moderna's Spikevax vaccine approval
  • Novavax's protein-based vaccine approval
  • FDA approval of Pfizer and BioNTech's Comirnaty vaccine with restrictions on age and health conditions
  • CDC guidance on high-risk conditions for severe COVID
  • Axios report on uncertainty around the nation's plan for COVID boosters
  • Statement from Robert F. Kennedy Jr. on the administration's regulatory approach to COVID-19 vaccines
  • STAT News report on the FDA's requirement for new trials on COVID-19 vaccine manufacturers
  • Pfizer and BioNTech's statement on their updated vaccine's availability and distribution